Novartis is taking its investigational gene therapy for a degenerative eye disease into clinical trials.

The molecule restores the activity of neurons and neural circuits in a model of the disease.

Great progress has been made against malaria, but signs of resistance are becoming a rising concern

What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

Chronic diseases like cancer and diabetes were once the preserve of wealthy countries but are now increasingly common in lower-income countries too as populations age and lifestyles change.

Novartis collaborates with the Banner Alzheimer’s Institute to test treatments for preventing Alzheimer’s disease.